Foster City, CA – According to filings with the U.S. Securities and Exchange Commission, Terns Pharmaceuticals is raising $97,703,068.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Senthil Sundaram played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single- agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. Terns’ programs are based on clinically validated and complementary mechanisms of action to address the multiple hepatic disease processes of NASH in order to drive meaningful clinical benefits for patients.

To learn more about Terns Pharmaceuticals, visit http://www.ternspharma.com/

Contact:
Senthil Sundaram, Chief Executive Officer
650-525-5535
https://www.linkedin.com/in/senthil1/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved